Linnaeus Therapeutics is a clinical-stage biotechnology company focused on the development of novel oncology therapies. The company was founded in 2016 in partnership the University of Pennsylvania's Penn Center for Innovation (PCI). Linnaeus’ lead Phase 2 compound, LNS8801, is a novel first-in-class, only-in-class, oral G-protein-coupled estrogen receptor (GPER) agonist. Activation of GPER by LNS8801 rapidly and durably depletes c-Myc protein. In an ongoing human phase 1/2A study LNS8801 monotherapy is safe, well-tolerated, and efficacious. Over 70% of patients with the correct biomarker, a fully-functional GPER genotype, benefit from therapy, and over 90% of patients with the correct biomarker and systemic target engagement have benefited from LNS8801 therapy. In addition, LNS8801 has shown strong efficacy in ICI-refractory patients when used as a monotherapy and in combination with check point inhibitors.  Linnaeus plans to initiate a randomized POC, potentially pivotal study in 2023 in PD-1 refractory cutaneous melanoma with a potential NDA by late 2025 and is actively prioritizing a 2nd indication between NSCLC, colorectal, or pancreatic cancers.  LNS8801 has composition of matter and methods of use patent protection into the 2040s and is easily manufacturable.

Founded in 2014, Innogen is a science-driven biotechnology company dedicated to the research and development of innovative and affordable medicines for diabetes and other metabolic disease patients. Innogen’s deep pipeline in metabolic disease that includes Type 1&2 diabetes, obesity, NASH etc. is independently developed and has global market rights.

Innogen has strong translational medicine capabilities and a team of experienced scientists in new drug development. Supaglutide, Innogen’s leading drug candidate, is a long-acting humanized GLP-1 receptor antagonist. Currently under phase III trials for T2D, Supaglutide will be the first humanized long-acting GLP-1 drug that originated from China. Continuously increasing diabetes patient population and sub-optimal glucose control provides an enormous potential market for Supaglutide both in China and across the globe. Other indications for Supaglutide such as obesity and NASH are also under development.

Viewpoint Molecular Targeting is a radiopharmaceutical company developing a pipeline of precision oncology therapeutics and complementary diagnostic imaging agents. Viewpoint’s leading Pb-212-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that utilize the same targeting peptide for the purpose of personalizing treatment and optimizing patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. Viewpoint has secured Pb-212 isotope supply by completing the development of its own proprietary generator. The company is headquartered in Coralville, Iowa where it has comprehensive in-house R&D laboratories and an experienced drug development team.

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn/.

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Functional Genome encodes information not only in linear sequence, also in its dynamic structure, location, and shape, the next gen multi-dimensional analysis technology will open unprecedented opportunities for diagnostic and therapeutic target discovery in the post T2T era.  We believe the conventional bottom-up balk solution genomics workflow is ok for primary germline genomic data, however compromised native sample integrity and obfuscated the heterogeneous clinically relevant biomedical information. Newly improved top-down workflow tailored to dynamic medical somatic samples and new 3D/4D Genomics technology is needed to transform the static genomic data deluge to truly useful medical information.

Dimension Genomics is a life science tool company developing such proprietary platform multidimensional genome analysis systems at subnuclear and subchromosomal level, with initial focus on complex aneuploidy, CIN, cancer/MRD and genetic diseases, accelerating medical grade cytopathological processing and data generation from the same patient sample, to solve the issues of disconnected genomic data type from various platforms. Serving tens of thousands of hospitals, independent reference labs, and biomedical Institutes worldwide, it has the potential to propel the projected next gen sequence and haploid resolved clinical cytopathology market towards $ 10+ billion in 2030. Founded by an experienced team who previously took an idea all the way to IPO and commercial products, company currently is in late stages of prototyping product-I with an oversubscribed seed round. 

Dyadic International (Nasdaq: DYAI) is a global biotechnology company applying its industrially proven microbial gene expression platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

Dyadic’s C1 protein production platform is based on the industrially proven fungus Thermothelomyces heterothallica which is used to speed development, lower costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.

Dyadic is also developing the Dapibus™ filamentous fungal based microbial protein production platform for the development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

We are leveraging our microbial platform technologies to develop our internal pipeline and to enable our collaborators to develop effective preventative and therapeutic treatments in developed and emerging countries.

To learn more about our C1 Technology please visit www.dyadic.com.

Shanghai Tenry Pharmaceutical Co., Ltd. is an innovative pharmaceutical enterprise established in 2010.  It mainly focuses on regenerative medicine and inflammatory disease areas with significant unmet medical needs, including wound healing, bleeding, asthma, and etc. . Tenry pharm possesses two leading products:  1)“Recombinant human acidic fibroblast growth factor” (rh-aFGF), 2)“recombinant Batroxobin for injection” (rBAT)

rh-aFGF is one of the best choice for wound healing. It has been launched in China market in 2015 with the approved indications of degree II burn wound and chronic unclers, . rh-aFGF is the only approved biological agent as the Lyophilized Recombinant Human Acidic Fibroblast Growth Factor for external use. More than 500,000 patients have been treated with rh-aFGF in the passing years.

rBAT is designed for the prevention and treatment of surgical bleeding and hemorrhagic diseases and has completed phase 3 clinical trials in China. This product is the first recombinant hemocoagulase product worldwide with a purity of 99%. Compared with snake venom extract (purity 90% ), it has obvious advantages in efficacy and safety, and does not cause thrombosis in normal blood vessels. The Global Hemostatic Agents market was valued at US$ 4.05 Billions in 2021 and is projected to reach a value of US$ 6.79 Billions by 2030, thus rBAT has great market potential and prospects in the future.

CStone is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received nine NDA approvals for four drugs. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

Founded in 2014, SystImmune Inc. is a US-based biotech company focused on the treatment of cancer through developing cutting-edge therapeutic bi-specific and multi-specific antibody-based drugs, as well as antibody-drug conjugates (ADCs). Our mission is to improve cancer patients’ quality of life by developing biologics that work through systematic intervention on tumor microenvironments, directly attacking the tumor and engaging the immune system.  SystImmune has developed three advanced biologics platforms, including the bi-specific antibody (SEBA), multi-specific antibody (GNC), and a novel ADC platform (HIRE). From these platforms, SystImmune has advanced eight assets into clinical development, including the world’s first-in-human tetra-specific antibody. The leading bi-specific asset, targeting EGFR and HER3, is in Phase 2 clinical trials for NSCLC, HNSCC, and other solid tumors. SystImmune’s R&D team supports numerous preclinical projects in the pipeline to expand on clinical successes and extend the impact of these three biologics platforms.

GV20 Therapeutics (寻百会) is a biopharmaceutical company with over 50 employees, and sites in Cambridge, Massachusetts and Shanghai, China. Its proprietary technology platform STEAD (simultaneous target evaluation and antibody discovery) integrates high-throughput functional genomics, artificial intelligence, and big data bioinformatics to exploit cancer vulnerabilities and find antibody drugs. STEAD uses bioinformatics extract tumor-infiltrating antibody sequences from tumor RNA-seq profiles, and AI to predict the targets of these antibodies. GV20 AI can not only de novo design antibodies against tumor targets enriched in functional binders and good developability profiles, but also rank immunogenic targets by their antibody signals in tumors. STEAD also utilizes CRISPR functional screens and big data bioinformatics to validate targets and inform target and drug mechanisms.

Applying the STEAD platform, GV20 identified a novel innate immune checkpoint in solid tumors with antigen presentation defects and predicted its antibodies. The lead antibody against this checkpoint demonstrated single-agent efficacy as well as synergy with anti-PD1 in tumor inhibition in multiple syngeneic tumor models. The lead program received IND approval from the FDA, with anticipated first patient dosing in the US in Q1.2023.

Founded in 2016, Help Thera-X is a globally clinical-stage biopharmaceutical company dedicated to the establishment of leading iPS Cell Bank as well as the development of first-in-class iPSC-derived cell therapeutics for degenerative diseases in the fields of cardiovascular system, nervous system and motor system. We have accumulated strong expertise and valuable real-world experience in multi-regional clinical trials centers in order to forward the development of human-iPSC-derived cardiomyocytes for heart failure filed by National Health Commission of China. We are committed to driving and empowering affordable innovation by our world-wide breakthrough in the development of cell manufacturing and quality control called Help Cell-foundry, which is composed of three major functional platforms combing machine learning and high-performing computing optimization. At Help Thera-X, we believe that the best way to deliver safe, effective and affordable cell therapy products is to provide superior development and manufacturing technologies, value and support at every stage of the journey to bring the next generation advanced therapies to patients in deed.

Founded in December 2017，Biocity is a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders including chronic kidney diseases (CKD).  The company has established a pipeline of more than 10 innovative drug candidates including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugates (ADCs).  There are 5 oncology projects in phase 1 development targeting the DDR pathway with a WEE1 and an ATR inhibitor, or the immune system with a T cell engager (CD3XEGFR BsAb), an immune checkpoint inhibitor (TIM-3 mAb), and a T cell activator (4-1BB mAb).  An IND has been submitted for a novel ADC which will initiate the first in human (FIH) trial in early 2023.  In addition, an endothelin A(ETA)-receptor selective antagonist designed for CKD has completed the FIH study and is entering into phase 2 development.

Website：www.biocitypharma.com

LongBio Pharma is a biotech company located in Shanghai, China. The company, which was founded in 2018, is focused on autoimmune and rare diseases, serving patients and society. The co-founder of LongBio Pharma, Dr. Sun, Bill, Nai-chau, is also the co-founder of Tanox, with its IPO in Nasdaq at 2000 and acquired by Genentech in 2007. He is also the co-inventor of Omalizumab (Xolair®, Global sales is 3.5B USD in 2021), the first anti-IgE antibody approved by FDA.

LongBio aims to bring our drugs to both domestic and international markets with our partners, especially to bring patients with more affordable and high-quality bio-medicines. Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is undergoing Phase I study, and is about to start Phase II in 2023Q1. The second leading pipeline is a bifunctional complement inhibitor (LP-005) intending to submit IND application in 2023Q1.

EarlyDiagnostics (EarlyDx) is a leader in liquid biopsy technologies, especially early cancer detection. Its cutting-edge technologies and strong IP portfolio were developed in collaboration with professors from UCLA/Stanford. EarlyDx’s breakthrough cell-free DNA methylome assay (cfMethyl-Seq), recently published in Nature Communications, offers a cost-effective approach for highly sensitive and specific pan-cancer early detection. The cfMethyl-Seq assay is robust and reproducible with even 1ng cfDNA input. Our cancer detection test, combining both the cfMethyl-Seq assay and proprietary algorithms, achieved 80.7% sensitivity in detecting cancers across all stages and 74.5% sensitivity in detecting early-stage (Stages I or II) cancer at a specificity of 97.9% (Nature Communications, 2022). Our test is further empowered by a centralized diagnostic informatics platform - EarlyDx-Cloud. This knowledge-based Cloud was integrated with the NCI Cancer Research Data Common infrastructure, supported by an NCI Phase I Contract. Currently, EarlyDx is conducting a multi-site clinical study, funded by an NIH SBIR Phase-2 award. Furthermore, EarlyDx’s technology is being evaluated with retrospective samples from nationwide clinical trials led by our academic collaborators. The company is seeking Series A funding to support clinical trials with a major hospital system and the commercial launch of its LDT test.

Rapafusyn Pharmaceuticals is a near-clinical stage company uniquely positioned for its well validated and differentiated “molecular glue” macrocycle drug discovery platform.

At the core of Rapafusyn’s platform are its proprietary diverse libraries of FKBP-binding bi-functional macrocycles that readily permeate cell membrane and concentrate intracellularly to self-assemble into protein-sized FKBP-macrocycle complexes. These complexes then present the disease-target-specific “effector domain” of the macrocycles to modulate challenging disease targets such as those undruggable by traditional small molecules, and have proven to exhibit “antibody-like” affinity and specificity towards a wide range of transmembrane and intracellular disease targets, including transporters, protein-protein-interaction, nuclear, and transcription factor targets.  

This platform has been validated in many in vivo efficacy models and demonstrated oral bioavailability and tunable CNS penetration.

Rapafusyn utilizes this platform both internally and with external pharma partners to discover game-changing therapeutics for diseases of high unmet needs.  Rapafusyn’s expanding preclinical drug pipeline tackles renal, oncological and neurological indications.  Rapadocin, its lead compound for acute kidney injury, is expected to be IND ready in about a year.  

With a world class team, Rapafusyn has a clear path to IPO & investor exit as early as 2025.  Its current fundraising plan includes an immediate A+ round for $5-$10 M and a B round in ~12 months.

ASC Therapeutics is a biopharmaceutical company pioneering the development of gene replacement therapies, in vivo gene editing and allogeneic cell therapies for hematological, metabolic, and other rare diseases. Led by a management team of industry veterans with significant global experience in gene and cell therapy, ASC Therapeutics is developing multiple therapeutic programs based on four technology platforms: 1) In-vivo gene therapy of inherited blood clotting disorders, initially focusing on ASC618, second generation gene therapy for hemophilia A, for which U.S. FDA IND clearance, Orphan Drug and Fast Track Designations were received; 2) In-vivo gene therapy in metabolic disorders, initially focusing on Maple Syrup Urine Disease, in collaboration with the Universities of Massachusetts and Pennsylvania; 3) In-vivo gene editing, initially focusing on ASC518 for hemophilia A; and 4) Allogeneic cell therapy, the first indication with a Decidua Stromal Cell-based therapy for steroid-refractory acute Graft-versus-Host Disease, for which U.S. FDA IND clearance and Orphan Drug Designation were received.

Sirnaomics Ltd. is a global, clinical-stage RNA therapeutics biopharmaceutical company that is discovering and developing innovative drugs for indications with significant unmet medical needs in cancer, fibrosis diseases, viral infections, liver-metabolic diseases, and medical aesthetics. Founded in 2007 in MD, USA, Sirnaomics has established a significant presence in both the U.S. and Asia with its own proprietary and novel delivery platforms for RNA-based therapeutics developing. its polypeptide nanoparticle delivery platform (PNP) is primarily used to administer mRNA vaccines and therapeutics and it's GalNAc delivery platform provides systemic administration for liver-targeting RNAi therapeutics.
Sirnaomics is the first to achieve positive Phase IIa clinical outcomes in oncology clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S. Backed by renowned institutional investors and industry experts, on 2021 December 31, Sirnaomics is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited.
Sirnaomics's mission is to become a fully integrated international biopharmaceutical company, leveraging our deep experience in RNA therapeutics and novel delivery platform technologies.